Swarnali Acharyya
Columbia University, USA

Dr. Swarnali Acharyya is an Assistant Professor in the Institute for Cancer Genetics at Columbia University. Dr. Acharyya completed her postdoctoral training at Memorial Sloan Kettering Cancer Center, New York and joined the faculty of Columbia University in 2014. Dr. Acharyya is studying how cancers induce systemic changes in muscle, which leads to cachexia. Her research efforts are focused on combining anti-metastasis therapies with anti-cachexia therapies to prolong cancer patient survival.

Volker Adams
TU Dresden, Heart Center, Germany

Volker Adams, PhD, is currently Head of Head of Research Laboratory Heart Center Dresden, Germany. He graduated in Biology from the University of Konstanz, Germany, and obtained his PhD there also. He was a fellow at the Baylor College of Medicine, Houston, TX, USA. He was awarded for the best oral presentation (Meeting of the working group Rehabilitation and Exercise Physiology of the European Society of Cardiology, Bergen/Norway, in 2001, and for President´s Lecture at the ACSM (American College of Sports Medicine) 2006 in Denver, CO, USA.

Markus Anker
Charité University Berlin, Germany

Dr. Markus Anker is working at the Department of Cardiology Campus Benjamin Franklin, Charité. His areas of expertise are heart failure, cardio-oncology, rhythmology, biomarkers.

Stefan D. Anker
Charité Campus Virchow Klinikum, Germany

Stefan D. Anker has been Professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. He was Professor of Cardiology & Cachexia Research at Charité from 2002 to 2014, and Professor of Innovative Clinical Trials in Göttingen, Germany, from 2014 to 2017.Prof. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle.

Hidenori Arai
National Center for Geriatrics and Gerontology (NCGG), Japan

Hidenori Arai (MD., PhD) is the President of the National Center for Geriatrics and Gerontology (NCGG), Japan since 2019. He is also the President of the Japan Gerontological Society, the Vice President of the Japan Geriatrics Society, the President of the Japanese Association on Sarcopenia and Frailty and the Vice President of the Japan Atherosclerosis Society. Additionally, he is the President of Asian Academy of Medicine for Ageing, and the Vice President of Asian Association of Frailty and Sarcopenia. He is a member of the Science Council of Japan since Oct. 2020.

José María Argilés-Huguet
University of Barcelona, Spain

Professor José María Argilés-Huguet was appointed Associated Professor (1986) at the University of Barcelona and has established his own line of research based on the study of metabolic adaptations to tumor growth and, in particular, the syndrome of cancerous cachexia. In 2003, he reached his current status as Professor of Biochemistry and Molecular Biology at the University of Barcelona. He is the author of several scientific books in the field of cancer and more than 390 scientific publications of more than 375 scientific publications. His contributions in the field of cancerous cachexia are known worldwide.

Didier Attaix
National Institute for Agricultural Research (INRA), France

Dr Attaix completed his PhD in Biochemistry at Université Blaise Pascal, France, and postdoctoral work at Harvard Medical School, USA. Dr Attaix’s career at the National Institute for Agricultural Research (INRA, France), has been devoted to the elucidation of mechanisms involved in the control of protein turnover and muscle mass, in both anabolic and catabolic conditions. Dr Attaix has been Research Director and head of the Proteolysis Group of the Human Nutrition Unit (INRA/Université Clermont Auvergne) for 27 years, with a major focus in ubiquitin-proteasome-dependent and lysosomal proteolysis.

Vickie Baracos
University of Alberta, Canada

The long-term focus of Dr. Baracos’ career has been the pathophysiology of skeletal muscle atrophy in an effort that encompasses fundamental and translational research, a clinical research agenda and an international network of strategic collaboration. Cancer cachexia, a debilitating condition characterized by profound atrophy of skeletal muscle, has been her focus since 2003. She developed the use of clinical computed tomography to detect and precisely measure the muscle loss which is an integral part of cachexia. Dr. Baracos received her BSc in animal science from the University of Alberta, her PhD in applied biochemistry from Nottingham University, and her PDF in physiology from Harvard Medical School.

Miguel Luiz Batista Júnior
Boston University School of Medicine, USA

Dr. Miguel Luiz Batista Júnior joined University of Mogi das Cruzes (UMC) in March 2010 after completing MASc from the University of São Paulo, Human Physiology program and a Ph.D. from the University of São Paulo, Cell and Tissue Biology program (2007). In 2020, he joined Farmer’s laboratory at Biochemistry Department in Boston University School of Medicine as Auxiliary Professor. His research interests include adipose tissue physiology in health, disease condition and aging. He has worked on in projects related to cellular and molecular analyses of adipose tissue remodeling in different experimental models of cancer cachexia.

Jürgen M. Bauer
Ruprecht Karls University Heidelberg, Germany

In 2016 Jürgen M. Bauer, MD, PhD, took over the newly established chair for geriatric medicine at the Ruprecht Karls University Heidelberg, Germany. In the same year Jürgen M. Bauer was elected to serve as the director of the Network Aging Research at Heidelberg University and he is also the director of the Agaplesion Bethanien Hospital Heidelberg. In 2010 he had been appointed director of the newly formed Centre for Geriatric Medicine Oldenburg, Germany, which is an integral part of the medical campus of the Carl von Ossietzky University Oldenburg. Between 2004 and 2010 he worked as assistant medical director at the Department of Geriatric Medicine at the University of Erlangen-Nuremberg, Germany.

Mauricio Berriel Diaz
Helmholtz Zentrum München, Germany

Mauricio Berriel Diaz, MD, PhD, trained in biology and obtained his PhD at the Philipps-University Marburg in Germany. He received postdoctoral training at the Max-Planck Institute for Heart and Lung Research, in Bad Nauheim, and then at the German Cancer Research Center (DKFZ) in Heidelberg. Since 2015, he has been the Deputy Director and Head of Division (Metabolism & Cancer) of the Institute for Diabetes and Cancer (IDC) which is a member of the Helmholtz Diabetes Center (HDC) at the Helmholtz Zentrum München and a partner in the joint Heidelberg-IDC Translational Diabetes Program. Dr. Berriel Diaz’ research interests include deciphering the mutual interactions between metabolic control and cancer, with an emphasis on the mechanisms underlying cancer-induced body weight loss (cachexia) as well as the impact of the metabolic macroenvironment on cancer development.

Olivier Bezy
Cellarity, USA

Dr. Olivier Bezy is a Director of Metabolism at Cellarity, a Flagship Pioneering company. Dr. Bezy completed his postdoctoral training in C. Ronald Kahn’s lab at Joslin Diabetes Center in Boston, and worked 9 years at Pfizer as a principal scientist in Internal Medicine Research Unit with special interest in obesity, diabetes and cachexia.

Andrea Bonetto
Indiana University, USA

Dr. Bonetto received his MSc in Industrial Biotechnology and his PhD in Experimental Pathology at University of Torino, Italy, working on investigating the molecular causes responsible for the development of cachexia, a severe complication of cancer. Currently, Dr. Bonetto is an Assistant Professor in the Department of Surgery at Indiana University and his main research interest is focused on understanding the effects of chemotherapy on muscle and bone, as well as on the overall energy metabolism, with the ultimate goal of identifying therapeutic strategies aimed at reducing the side toxicity of anticancer treatments and at improving the quality of life in cancer patients.

Marc Bonnefoy
University Hospital Lyon, France

Prof. Marc Bonnefoy is Head of the Geriatrics Department of the University Department of Medicine for Ageing in Lyon. He has been in charge of the department since 1991, which he developed by creating a complete geriatric sector with an outpatient focus: memory consultations, oncogeriatrics, nutrition, assessments, prevention programmes, HDJ, intra- and extra-hospital mobile teams, Hotline (current team of around 12 senior doctors). Prof. Bonnefoy is a member of the national professional college of geriatrics (CNP), member of the Board of the SFGG and has been appointed expert by the High Council of Public Health on the Nutrition WG (2019)-

Scott C. Brakenridge
University of Florida Health Science Center, USA

Scott Brakenridge, MD, MSCS, FACS, is an Associate Professor of Surgery & Anesthesiology at the University of Florida. He is dual-board certified in General Surgery and Surgical Critical Care by the American Board of Surgery, and is a Fellow of the American College of Surgeons. Dr. Brakenridge is one of the primary investigators and core leaders of the University of Florida Sepsis & Critical Illness Research Center. His research focuses on clinical, and translational research approaches to investigate chronic critical illness (CCI), and the persistent inflammation, immunosuppression and catabolism syndrome (PICS) after surgical sepsis or severe traumatic injury.

Ruta Brazauskas
Medical College of Wisconsin, USA

Dr. Ruta Brazauskas is an Associate Professor in the Division of Biostatistics at the Medical College of Wisconsin, Milwaukee, USA. Dr. Brazauskas’ research interests include survival analysis and competing risks. She serves as a biostatistician for the Center for International Blood and Marrow Transplant Research (CIBMTR) and Primary Immune Deficiency Treatment Consortium (PIDTC). Her duties involve designing research studies and clinical trials and performing statistical analysis of the data from medical studies. Most of her collaborative work is in the area of stem cell transplantation (HCT) with strong emphasis on long-term outcomes and quality of life following HCT. Dr. Brazauskas has published 90 peer-reviewed papers. She also received several awards for excellence in teaching biostatistics.

Bette Caan
Kaiser Permanente Northern California Division of Research, USA

Dr. Bette Caan is a senior research scientist and a nutritional epidemiologist at the Kaiser Permanente Northern California Division of Research. She has been at the Division of Research since 1983. Dr. Caan holds a master’s degree in nutrition from Columbia University, a master’s degree in epidemiology from the University of California, Berkeley, and a doctorate in public health nutrition from the University of California, Berkeley. Dr. Caan directs a research program in the examination of modifiable lifestyle risk factors for the prevention and progression of cancer, with a focus on body composition and energy balance risk factors.

James A. Carson
University of Tennessee Health Science Center, USA

James A. Carson, Ph.D., serves as the Senior Associate Dean for Research and Graduate Studies in the College of Health Professions at the University of Tennessee Health Science Center in Memphis and is a Professor in the Department of Physical Therapy. While serving on the faculty at the University of South Carolina (USC) for 19 years, he held the rank of Professor, was Department Chair for Exercise Science, and Associate Director of the Center for Colon Cancer Research at USC. He has received several million dollars in external research funding, with the majority coming from the NIH as the principal investigator.

Andreas Charalambous
Cyprus University of Technology, Republic of Cyprus

Dr. Andreas Charalambous is the Chair of the Nursing Department at the Cyprus University of Technology where he works as an Associate Professor of Oncology and Palliative Care and he holds the position of an Adjunct Professor at University of Turku (Finland). He is the founder and Past-President of the Cyprus Oncology Nursing Society and EONS President. He is co-chair of the Workforce Network of the European Cancer Organisation and member of the Scientific Advisory Board of SPCC.

Andrea Cheville
Mayo Clinic, USA

Dr. Andrea Cheville is a Professor of Physical Medicine and Rehabilitation and is the Physical Medicine and Rehabilitation Department Chair at Mayo Clinic in Rochester, MN. She received her MD degree from Harvard Medical School in 1993 and her Master of Science in Clinical Epidemiology degree from the University of Pennsylvania in 2006. Her areas of clinical and research interest are lymphedema and cancer rehabilitation, palliative medicine, and patient-reported outcomes. She is board-certified in Physical Medicine and Rehabilitation, Pain Medicine, and Palliative Care. She has received funding from the National Institutes of Health, National Cancer Institute, and the U.S. Department of Defense. She was elected to the National Institute of Medicine in October 2016.

Jesper Frank Christensen
Rigshospitalet – Copenhagen University Hospital, Denmark

Dr Jesper Frank Christensen, PhD, M.Sc. is a Senior Researcher and Group Leader at the Centre for Physical Activity Research (CFAS), Rigshospitalet, Copenhagen University Hospital and an Associate Professor at the University of Southern Denmark. Over the last decade, he has been the Principal Investigator for clinical exercise-trials across a wide range of malignancies including testicular, prostate, colorectal, and gastro-oesophageal cancers. His current exercise-oncology research program spans the translational ‘bench-bedside-practice’ spectrum of biomedical research to elucidate and integrate information on the biological mechanisms, clinical effects and practice-based implications of exercise training in the oncology setting.

Andrew J.S. Coats
Monash University, Australia

Andrew Coats is an expert on heart failure. He first described the Muscle Hypothesis of Chronic Heart Failure that explained dyspnoea and exaggerated ventilatory responses in CHF patients. He first described chemoreflex overactivity in CHF and periodic breathing and published the first ever randomised trial of exercise training for CHF. He has served Head of Cardiology at Imperial College and Director of Cardiology at Royal Brompton Hospital, London then as Dean of Medicine and Deputy Vice-President at the University of Sydney, and as Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. He is President Elect of the Heart Failure Association of the ESC.

Paola Costelli
University of Torino, Italy

Paola Costelli has Degree in Biological Sciences, PhD in Experimental and Molecular Pathology and is Full Professor of Pathology at the Department of Clinical and Biological Sciences, University of Torino, Italy. She is Group leader since 1999, her main research interest being the study of the mechanisms underlying the pathogenesis of muscle wasting in cancer cachexia, particularly focusing on the alterations of proteostasis and myogenesis.

Jeffrey Crawford
Duke Cancer Institute, USA

Jeffrey Crawford, MD, is George Barth Geller Professor for Research in Cancer and Lead PI of NCTN LAPS Grant in the Duke Cancer Institute (DCI) in Durham, North Carolina. Dr. Crawford served as Chief of the Division of Medical Oncology for 10 years prior to assuming his current leadership roles. He served as Chair of NCCN Myeloid Growth Factors Panel for 15 years. Dr. Crawford is Principal Investigator for the National Clinical Trials Network Lead Academic Site Grant at Duke. His research interests include new treatment approaches to lung cancer, supportive care therapies, including hematopoietic growth factors and biosimilars, and agents that impact muscle wasting.

Srinivasan Dasarathy
Cleveland Clinic Lerner College of Medicine, USA

Dr. Srinivasan Dasarathy is a Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine. In addition to his clinical activities as a board certified gastroenterologist and transplant hepatologist, he is also the Director of Liver Metabolism Research in the Center for Human Nutrition. He has worked on dissecting the mechanisms of sarcopenia in hyperammonemia, hypoxia and ethanol exposure in the secondary pathogenesis of sarcopenia in multiple chronic diseases. He is an independently funded investigator and his laboratory uses an integrated molecular metabolic approaches in a comprehensive array of models including preclinical studies in cellular and animal models and translational research in human subjects.

Hans Degens
Manchester Metropolitan University, United Kingdom

Hans Degens received his MSc degree in Biology at the Wageningen University and Research in 1988 and his PhD in Exercise Physiology at the Radboud University Nijmegen in 1993. He was a post-doctoral researcher at the University of Liverpool (1994-1995), the Karolinska Institute Stockholm (1995-1997), the University of South Florida Tampa (1997-1999) and the University of Maastricht (1999-2004). He was an Assistant Professor Physiology at the Radboud Univerity Nijmegen (2002-2004) and works since 2004 at the Manchester Metropolitan University where he became Professor in 2015. He received an Honorary Doctorate from the Lithuanian Sports University Kaunas in 2017, and he is visiting professor at that university since 2015.

Egidio Del Fabbro
Virginia Commonwealth University Massey Cancer Center, USA

Egidio Del Fabbro, M.D., is the Palliative Care Endowed Chair and Program Director at Virginia Commonwealth University Massey Cancer Center. Dr. Del Fabbro also serves as a Professor of Internal Medicine within the Division of Hematology, Oncology and Palliative Care of the Department of Internal Medicine at the VCU School of Medicine. His clinical research is focused on therapeutic interventions for symptoms in patients with cancer, and opioid related side-effects. He was the Principal Investigator of two randomized, placebo-controlled trials for poor appetite and cancer-related fatigue in patients with advanced cancer.

Cynthia Delgado
University of California, USA

Cynthia Delgado MD, is an Associate Professor of Medicine with the San Francisco Veterans Affairs Healthcare System and University of California, San Francisco. She is the director of the dialysis program at the San Francisco VA. She is also the Chair of the Diversity and Inclusion Committee for the American Society of Nephrology and the co-chair of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. She is a recognized U.S. national expert on functional status, frailty, body composition, quality of life and related outcomes among individuals with chronic kidney disease.

Nicolaas Deutz
Texas A&M University, USA

Dr. Deutz is a Professor and Director of the Center for Translational Research in Aging & Longevity, Director of Clinical Research, Human Clinical Research Building, Department of Health & Kinesiology, Texas A&M University. His research and interests have been in clinical nutrition and metabolism research in animals and humans for more than 30 years and he has published over 300 papers. His clinical interest is using nutritional supplements to treat malnutrition in older adults and during acute and chronic disease states. He has focused his research on (inter)organ protein and amino acid metabolism using animals, healthy humans, and patients with various acute and chronic diseases, including (pre)diabetes, obesity, cancer, COPD.

Wolfram Doehner
Charité – Universitätsmedizin Berlin, Germany

Wolfram Doehner, MD, PhD, FESC, FHFA is Professor of Interdisciplinary Stroke Research at the Charité – Universitätsmedizin Berlin, Germany. He is a Cardiologist and specialist for internal medicine and for nutritional medicine. He works at the Berlin Institute of Health-Center for Regenerative Medicine (BCRT) and at the Dept. of Cardiology at the Virchow hospital of the Charite University medical center. He holds also a position at the Center for Stroke Research Berlin (CSB). His research focus is on skeletal muscle metabolism, insulin sensitivity and abnormal muscle wasting in chronic diseases and during rehabilitation.

Jason Doles
Mayo Clinic, USA

Dr. Jason Doles is an Assistant Professor in the Department of Biochemistry and Molecular Biology at Mayo Clinic. He received a B.A. in Political Science and Biology from Brown University, and a Ph.D. in Biology from the Massachusetts Institute of Technology. Following postdoctoral fellowships at the Center for Genomic Regulation (Barcelona, Spain) and the University of Colorado-Boulder, Dr. Doles moved to Mayo Clinic in 2016, where he leads a basic science research lab focused on stem cells, tissue regeneration, and multi-organ wasting. In addition to research, he is an advocate for diversity in STEM and is currently serving as the Assistant Dean for Diversity and Inclusion within the Mayo Clinic Graduate School of Biomedical Sciences.

Gustavo Duque
University of Melbourne, Australia

Prof. Gustavo Duque MD, PhD, FRACP, FGSA is a geriatrician and a clinical and biomedical researcher with special interest in the mechanisms and treatment of osteoporosis, sarcopenia and frailty in older persons. Prof. Duque’s major research interests include the elucidation of the mechanisms and potential new treatments for age-related bone loss, osteoporosis, sarcopenia and frailty. He is currently Chair of Medicine and Director of the Australian Institute for Musculoskeletal Science (AIMSS) at the University of Melbourne and Western Health. He is also Director of the Fracture Care and Prevention Program at Western Health (Melbourne).

William J. Evans
Duke University Medical Center, USA

William J. Evans, PhD is a Professor of Medicine at the Duke University Medical Center and Professor of Human Nutrition in the Department of Nutritional Sciences at the University of California, Berkeley. He has served as laboratory director at the Reynolds Institute on Aging at the University of Arkansas for Medical Sciences, the Noll Physiological Research Center at the Pennsylvania State University as the Chief of the Human Physiology Laboratory at the Human Nutrition Research Center on Aging at Tufts University. He is a Fellow of the American College of Sports Medicine, The American College of Nutrition, and an honorary member of the Academy of Nutrition and Dietetics.

Jerome N. Feige
Nestlé Research, Switzerland

Dr Jerome N. Feige is the head of the Musculo-Skeletal department of Nestlé Research in Lausanne, Switzerland, and a recognized expert in muscle and aging biology. He worked as laboratory head at the Novartis Institute of Biomedical Research in Basel, Switzerland, where he performed drug discovery for muscle diseases and contributed to the development of new therapies currently in late stage clinical testing. Since 2012, Dr Feige has held increasing responsibilities in the Nestlé Institute of Health Sciences where he established a research program studying muscle biology and a translational department developing nutritional therapies to support the Musculo-Skeletal system. Dr Feige is also an adjunct lecturer at the Ecole Polytechnique Fédérale de Lausanne (EPFL) where he teaches nutrition and biology, and trains PhD students in biomedical science.

Roger A. Fielding
Tufts University School of Medicine, USA

Roger A. Fielding, Ph.D. is Associate Director of the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and serves as Director and Senior Scientist of the Nutrition, Exercise Physiology, and Sarcopenia (NEPS) Laboratory. He is also Professor of Nutrition at the Friedman School of Nutrition Science and Policy, Professor of Medicine at Tufts University School of Medicine and the Associate Director of the Boston Claude D. Pepper Older Americans Independence Center. Dr. Fielding is an internationally known researcher who studies the underlying mechanisms contributing to the age-associated decline in skeletal muscle mass, the resultant impact on function, and the potential role of exercise, nutrition, physical activity and other therapies on attenuating this process.

Kevin Flanigan
Nationwide Children’s Hospital, USA

Kevin Flanigan, M.D., is the Director of The Center for Gene Therapy at Nationwide Children’s Hospital in Columbus, Ohio, where he holds the Robert F. & Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research. He directs the NCH Neuromuscular Program as well as Nationwide Children’s NIAMS P50-funded Center for Research Translation (CORT) in Muscular Dystrophy Therapeutic Development. His research focuses on genotype/phenotype correlations in the muscular dystrophies, with a goal of understanding molecular mechanisms that lead to amelioration of symptoms in order to identify new therapeutic pathways. His laboratory works primarily on AAV-based approaches to gene therapy, including viral-vector based exon skipping and gene replacement.

Jose M. Garcia
University of Washington in Seattle, USA

Dr. Jose M. Garcia, M.D., Ph.D., is a Clinician and Scientist at the Puget Sound VA and an Associate Professor of Medicine at the University of Washington in Seattle, WA, USA. His current research focuses on the role of ghrelin, androgens and other anabolic pathways in different wasting conditions including sarcopenia of aging and cancer cachexia. His basic lab is focused on understanding molecular pathways involved in the development of muscle wasting, fat atrophy and anorexia in these settings, and in the development of novel targets for these conditions. His group is also involved in several human trials in patients with cancer anorexia and cachexia aiming at characterizing the pathways involved, identifying the mechanisms of action of different potential therapies and testing them in multicenter trials.

Sven Geissler
Charité – Universitätsmedizin Berlin, Germany

Dr. Sven Geissler currently works as leader of the Prognostic Markers and Targeted Therapies Group and deputy head of the Musculoskeletal System Research Area at the Berlin-Brandenburg Center for Regenerative Therapies, Charité Universitätsmedizin Berlin in Germany. The group aims to develop new prognostic and therapeutic procedures for compromised regeneration of the musculoskeletal system. Dr. Geissler has published 48 peer-reviewed articles and is associate editor of the Journal of Cachexia, Sarcopenia and Muscle, guest editor of Frontiers in Immunology and a reviewer for several other journals.

David Glass
Regeneron Pharmaceuticals, USA

David Glass, MD, has been the Vice President of Research and head of the Postdoctoral fellow program at Regeneron Pharmaceuticals, Inc. since 2019, and he also served in numerous roles from Staff Scientist to Vice President of the Muscle Program at Regeneron from 1991 – 2005. In between his work at Regeneron, he was Executive Director of the Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. Dr. Glass serves on both the Board of Directors and Scientific Advisory Board of the FSHD Society and is a Senior Lecturer in the Department of Cell Biology at Harvard Medical School. He holds a BA from Columbia College, an MD from New York Medical College and conducted postdoctoral work at Columbia University.

Marcus D. Goncalves
Weill Cornell Medical College, USA

Marcus Goncalves MD, PhD, is an endocrinologist and basic scientist at Weill Cornell Medical College in New York. His research focuses on the interactions between cancer and the metabolites and hormones that regulate systemic metabolism. As a practicing endocrinologist, he has developed therapeutic and dietary strategies to modulate metabolism in patients with cancer, and he is currently involved in several clinical studies to assess the effects of dietary interventions in this population. Dr. Goncalves is in receipt of a National Cancer Institute Career Development Award and is the founder of the strength and appetite clinic at Weill Cornell, which cares for patients with cancer-induced cachexia and other metabolic disease.

Denis Guttridge
Medical University of South Carolina (MUSC), USA

Dr. Denis Guttridge is a Professor in the Department of Pediatrics at the Medical University of South Carolina (MUSC). He received his Bachelors of Science degree from the University of California, San Diego, where he majored in Cell Biology and Biochemistry. After receiving a Master’s Degree in Biochemistry from Long Beach State University, he obtained his Ph.D. in Biological Sciences from the University of California, Irvine, and subsequently performed postdoctoral training at the Lineberger Cancer Center at the University of North Carolina, Chapel Hill. As a postdoctoral fellow, Dr. Guttridge performed studies to examine the role of a transcription factor called NF-κB in regulating the differentiation of cells.

Stephan Herzig
Institute for Diabetes and Cancer IDC, Helmholtz Center Munich, Germany

Stephan Herzig completed his PhD in 1999 at the University of Gottingen, Germany. After postdoctoral studies at the Salk Institute, La Jolla, CA, he established an independent Junior Research Group at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, in 2004. In 2010, he became Head of the “Molecular Metabolic Control” Department at the DKFZ, and between 2012 and 2014 headed a joint research division between the DKFZ, Heidelberg University and Heidelberg University Hospital. Since 2015, he has been Full Professor at the Munich Technical University Medical Faculty and Honorary Professor at the Heidelberg University Medical Faculty. He is also currently Director of the Institute for Diabetes and Cancer (IDC), Scientific Director of the Helmholtz Diabetes Center (HDC) and Research Director of the Helmholtz Zentrum München that is a partner in the joint Heidelberg-IDC Translational Diabetes Program, in Neuherberg, Germany.

Steven B. Heymsfield
Louisiana State University System, USA

Steven B. Heymsfield, M.D. is Professor and Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center of the Louisiana State University System in Baton Rouge. Dr. Heymsfield stepped down as Executive Director of Pennington Biomedical in 2013 to assume his current position. He has published more than 600 peer-reviewed papers covering topics such as obesity, malnutrition, sarcopenia, cachexia, body composition, and caloric expenditure. Dr. Heymsfield was elected Fellow of The Obesity Society, the American Society of Nutrition, and the Society on Sarcopenia, Cachexia, and Wasting Disorder, and he is an honorary member of the American Dietetic and Chilean Clinical Nutrition Associations. Dr. Heymsfield serves on the Dietary Guidelines for Americans 2020-2025 Committee.

Alp Ikizler
Vanderbilt University School of Medicine, USA

Dr. Ikizler is currently the Director of Division of Nephrology and Hypertension, Professor of Medicine and Catherine McLaughlin Hakim Chair in Vascular Biology at the Vanderbilt University School of Medicine in Nashville, Tennessee. He is a member of American Society of Clinical Investigation (ASCI), Association of American Physicians (AAP), and FASEB Board of Directors. Dr. Ikizler’s clinical and research interests and expertise are focused on the care of the patients with chronic kidney disease, end-stage kidney disease on maintenance dialysis and acute kidney injury. He has research and clinical interest in nutritional and metabolic aspects of acute and chronic disease.

Aminah Jatoi
Mayo Clinic, USA

Aminah Jatoi, M.D., is Professor of Oncology and the Betty J. Foust, M.D. and Parents’ Professor of Oncology at Mayo Clinic in Minnesota, where she primarily cares for patients with gastrointestinal and gynecological malignancies. Her research focuses on supportive care issues in cancer patients with a particular interest in cancer-associated weight loss. The author of 350+ publications, she seeks to mitigate side effects from the cancer treatment and distressing signs and symptoms related to the cancer itself. Her research has been funded by National Cancer Institute and various foundations.

Masaaki Konishi
Yokohama City University School of Medicine,Japan

Masaaki Konishi, MD, PhD, obtained his PhD from the Yokohama City University, Graduate School of Medicine, after having graduated MD in 2002 from the Yokohama City University, School of Medicine.
He performed his residency in Yokohama, and from 2004-2014, working in the Department of Medical Science and Cardiorenal Medicine, Yokohama City University. In 2014, he was appointed Guest Researcher at the Charité Medical School, Berlin, and at the University of Göttingen Medical School, Göttingen, Germany, until being appointed Assistant Professor, in the Department of Medical Science and Cardiorenal Medicine, at Yokohama City University School of Medicine in 2016.

Mitja Lainscak
University of Ljubljana, Slovenia

Dr. Mitja Lainscak is Professor at Faculty of Medicine, University of Ljubljana and does clinical practice & research at Division of Cardiology, General Hospital Murska Sobota, Slovenia. His clinical and research interest is cardiovascular medicine with particular emphasis on heart failure, epidemiology, comorbidities (with particular emphasis on lung involvement), pharmacotherapy, and metabolism with body composition. For several years he in engaged with European Society of Cardiology and Heart Failure Association of the ESC boards and committees, and is a Fellow of the HFA and of the ESC. In 2018, he was the Scientific Chairperson of the Heart Failure Association annual congress.

Francesco Landi
Catholic University of Rome, School of Medicine, Italy

Francesco Landi is Associate Professor of Internal Medicine at the Catholic University of Rome, School of Medicine. He is the chief of the Geriatric Internal Medicine Unit of the Geriatrics Department of the A. Gemelli University Hospital. Prof. Landi serves as a President of the Scientific Committee of the Italian Geriatric Society, on the Editorial Board of several international geriatric journals, and as a peer reviewer for numerous international medical journals. He has acted as the Principal Investigator in many multicenter national and international trials. In addition, he is a member of national and international expert groups that work on guidelines in the field of nutrition, sarcopenia and functionality in older adults.

Alessandro Laviano
Sapienza University of Rome, Italy

Alessandro Laviano, MD, is associate professor of Internal Medicine at the Department of Translational and Precision Medicine, Sapienza University of Rome, Italy. Dr. Laviano is Chief, Clinical Nutrition Unit at Sant’Andrea University Hospital in Rome, Italy. Also, Dr. Laviano holds a position of Visiting Research Professor at Upstate Medical University, Syracuse, NY, USA. Dr. Laviano’s main research interests are: disease-associated anorexia and cachexia, and particularly cancer cachexia; nutritional modulation of anticancer treatments; hyperphagia and obesity; neural control of metabolism; hospital malnutrition. He is currently the Director of the ESPEN LLL programme, as well as Coordinator of the Supervisory Board of the ESPEN project, nutritionDay.

Jennifer G. Le-Rademacher
Mayo Clinic, USA

Jennifer G. Le-Rademacher is Professor of Biostatistics with a joint appointment of Professor of Oncology at Mayo Clinic in Rochester Minnesota, USA. She has been a faculty biostatistician for multi-center cancer clinical trials for 12 years. Her clinical research areas include blood and bone marrow transplantation, treatments for prevention or palliation of toxicities related to cancer or caused by cancer therapy, and the impact of cancer treatment in older patients. Her statistical areas of expertise include clinical trial designs, observational studies, survival analysis, longitudinal data analysis. She have co-authored more than 100 publications and have been invited to give presentations at numerous national/international conferences.

Stef Levolger
University Medical Center of Groningen, The Netherlands

Stef Levolger is an interventional radiology resident in his last year of training, currently affiliated with the University Medical Center of Groningen. He completed his PhD in medicine at the Erasmus Medical Center in Rotterdam, on the subject of ‘Skeletal Muscle Wasting, its clinical implications and experimental treatment’ in which the impact of low skeletal muscle mass was investigated in various surgical oncology populations and liver transplant candidates. Recent research also includes the importance of skeletal muscle wasting in patients with peripheral cardiovascular disease and AI driven quantification of skeletal muscle mass.

Yi-Ping Li
University of Texas Health Science Center, USA

Dr. Yi-Ping Li, Ph.D., is currently a Professor in the Department of Integrative Biology and Pharmacology at The University of Texas Health Science Center at Houston. He received the Ph.D. degree in pharmacology from Texas Tech University Health Science Center in 1990, and completed postdoctoral training in the Department of Biochemistry and Molecular Biology at The University of Texas Southwestern Medical Center in Dallas in 1994. He joined Baylor College of Medicine in 1994 and moved to The University of Texas Health Science Center at Houston in 2009. His research focuses on skeletal and cardiac muscle remodeling in pathological conditions such as cancer, sepsis and other diseases.

Hanns Lochmüller
University of Ottawa Faculty of Medicine, Canada

Hanns Lochmüller is a neurologist and clinical academic specializing in genetic neuromuscular disorders and rare disease. He is Senior Scientist at the Children’s Hospital of Eastern Ontario (CHEO) Research Institute. He also holds appointments as Professor of Neurology in the University of Ottawa Faculty of Medicine and the Department of Medicine, Division of Neurology at The Ottawa Hospital. He is affiliated with the University of Ottawa Brain and Mind Research Institute and Department of Cellular and Molecular Medicine and with the Ottawa Centre for Neuromuscular Disease.

Gordon S. Lynch
University of Melbourne, Australia

Gordon Lynch is Professor of Physiology and Director of the Centre for Muscle Research in the Department of Physiology at The University of Melbourne. The Centre is a basic science discovery hub linking muscle-themed research across the university’s faculties and affiliated research institutes and hospitals, including biomedicine, engineering, and agriculture. His research on muscle adaptation, injury and regeneration investigates causes and treatments for muscle wasting and weakness in ageing, cancer, and the muscular dystrophies. He is most recently, President of the Australian Physiological Society (2017-2020) and is Scientific Director of the Australian and New Zealand Society for Sarcopenia and Frailty Research (2017–). Twitter: @GordonSLynch

Andrea B. Maier
University of Melbourne, Australia

Professor Maier, a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from Universität zu Lübeck (University of Lübeck, Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and 2013 was appointed Professor of Gerontology at Vrije Universiteit Amsterdam (VU University Amsterdam, The Netherlands). Since 2016 Professor Maier has served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. Professor Maier’s research focuses on unraveling the mechanisms of aging and the interaction of aging and age-related diseases.

Robert Mak
University of California San Diego, USA

Robert Mak, MD, PhD, FAAP, FRCP is Professor of Pediatrics on the Ladder Series with tenure at the University of California San Diego and Chief of the Division of Pediatric Nephrology at Rady Children’s Hospital of San Diego. He has served as Councilor representing the United States and also as Chair of the Global Education Committee of the International Pediatric Nephrology Association. He has served on several Study Sections at the National Institute of Health (NIH). He was the co-founder and President of the Western Society of Pediatric Nephrology. He has served as Associate Editor for Pediatric Nephrology Journal, Editorial Board member for the Pediatric Research Journal and the Clinical Journal of the American Society of Nephrology.

Daniel L. Marks
OHSU, USA

Daniel L. Marks M.D., Ph.D. received medical and graduate training at the University of Washington, then completed his pediatric residency at the University of Utah, and a fellowship in pediatric endocrinology at OHSU. He is currently Senior Associate Dean for Research at OHSU. He is also Professor in Pediatric Endocrinology, Ray Hickey Chair for Pediatric Research, Director of the Papé Family Pediatric Research Institute, and Associate Director of the OHSU MD PhD program. His current investigations are focused on the neuroendocrine control of body weight. He has a particular interest in the brain mechanisms of disease-associated cachexia, with emphasis on cachexia in cancer patients and children with chronic disease.

Emanuele Marzetti
Università Cattolica del Sacro Cuore, Italy

Emanuele Marzetti is a board certified Geriatrician, Clinical Assistant Professor in Geriatrics, and the leader of the Orthogeriatric Unit at the Department of Geriatrics, Neurosciences and Orthopedics (Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS at the Università Cattolica del Sacro Cuore, Rome, Italy). Since 2009, he has been the scientific director Biogerontology Laboratory of the Center of Geriatric Medicine (Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS at the Università Cattolica del Sacro Cuore, Rome, Italy). His research focuses on the mechanisms responsible for skeletal muscle and cardiovascular aging, with a special interest in mitochondrial pathophysiology, biomarker discovery, and the factors leading to frailty and disability in older adults with chronic degenerative conditions.

Asmita Mishra
Moffitt Cancer Center, USA

Asmita Mishra, MD earned a medical degree from St. George’s University, Grenada, in 2007 and a bachelor’s degree in psychology from New York University in 2002, and is an Associate Member at the Moffitt Cancer Center’s Department of BMT and Cellular Immunotherapy and an Associate Professor of Medicine and Oncology in the Department of Oncology Sciences of the Morsani College of Medicine. She is an affiliate member of the USF Women’s and Gender Studies Department and is certified by the American Board of Internal Medicine, the American Board of Internal Medicine-Hematology and the American Board of Internal Medicine-Medical Oncology. Dr. Mishra’s clinical and research interests include molecular therapies for myeloid disorders and developing improved transplant regimens for the frail and elderly.

Frank Misselwitz
Bayer AG, Germany

Frank Misselwitz, MD, PhD, is currently Corporate Vice President and Executive Scientist Thrombosis/Cardiorenal at Bayer AG, Wuppertal, Germany where he led the Therapeutic Area Cardiovascular and Thrombosis within Clinical Development for 15 years.
He has been responsible for the worldwide clinical development of rivaroxaban since 2002. He was involved in the planning and execution of the phase II and III clinical studies, and is currently heavily involved in the planning and execution of late life cycle studies. In 2005 he became Vice President and Head of the Therapeutic Area Cardiovascular and Coagulation. Under his leadership Adempas (Riociguat) was successfully developed and approved to treat Pulmonary Arterial Hypertension and Chronic Thrombo-Embolic Pulmonary Hypertension.

John E. Morley
St Louis University, USA

John Morley is a geriatrician and endocrinologist. He is a Professor Emeritus at St Louis University. He is Director of the Missouri GWEP. His research areas are frailty, sarcopenia, anorexia, dementia, and AI.

Kate T. Murphy
University of Melbourne, Australia

Kate Murphy is a Victorian Cancer Agency Research Fellow in the Centre for Muscle Research, Department of Physiology, The University of Melbourne. Her research relates to understanding the mechanisms underlying muscle wasting conditions, including cancer cachexia and investigating potential therapeutic strategies. Kate completed her B. Appl. Sci. at Deakin University, her B. Appl. Sci. Honours and Ph.D. at Victoria University and early postdoctoral training at the University of Aarhus, Denmark. She has been a Research Fellow in the Department of Physiology at The University of Melbourne since 2007 and was awarded a National Health and Medical Research (NHMRC, Australia) Peter Doherty Biomedical Research Fellowship, an NHMRC Career Development Research Fellowship and a Victorian Cancer Agency Research Fellowship (2020-2024).

Maurizio Muscaritoli
Sapienza University of Rome, Italy

Maurizio Muscaritoli, MD, is a Full Professor of Internal Medicine and Director, Internal Medicine and Clinical Nutrition Unit and Vice-Director of the Department of Translational and precision Medicine, Sapienza University of Rome, Italy. Director, Internal Medicine Residency Program at Sapienza University of Rome. Chairman, Italian Society of Clinical Nutrition and Metabolism (SINuC). Coordinator, ESPEN NESG/NEMS working group on Education; Coordinator, ESPEN Cachexia-Anorexia in Chronic Diseases Special Interest Group. Section Chief Editor, Frontiers in Clinical Nutrition. Associate Editor, Clinical Nutrition, JCSM. Board member of SCWD. Main research interests are cancer cachexia -pathophysiology and treatment-, mechanisms of sarcopenia, malnutrition, clinical nutrition, body composition changes in chronic diseases. Author of numerous publications in indexed journal on the same topics.

Gustavo Nader
The Pennsylvania State University, USA

Gustavo Nader, Ph.D., is Associate Professor of Kinesiology at The Pennsylvania State University, USA. Gustavo Nader researches skeletal muscle growth control and adaptations to exercise. Ribosome biogenesis, transcriptional and epigenetic regulation of RNA Polymerase I. Dr. Nader’s research continues to focus on the regulation of ribosome biogenesis and its role in the regulation of muscle growth by employing human, animal and cell models of muscle hypertrophy. Additionally, the lab seeks to decipher biomimicry approaches employed by hibernators to define novel strategies to preserve skeletal muscle mass.

Fabio Penna
University of Torino, Italy

Fabio Penna obtained his PhD in Experimental and Molecular Pathology. He is Assistant Professor and Teacher of General Pathology at the University of Torino, Italy, and was formerly visiting scientist in reference laboratories for the study of skeletal muscle in health and disease. His research focus spans from unveiling the underlying mechanisms of cancer cachexia to setting up innovative therapeutic strategies in preclinical model systems. He is also an expert in exercise training, mitochondrial function, proteolysis, autophagy and myogenesis. He has published over 60 papers in peer-reviewed international journals (H index: 27) and led scientific projects on cancer cachexia. He is Associate Editor of the Journal of Cachexia, Sarcopenia and Muscle (Rapid communications).

Joanne Reid
Queen’s University Belfast, United Kingdom

Joanne Reid is a Professor of Cancer and Palliative Care and Director of Research in the School of Nursing and Midwifery in Queen’s University Belfast. Professor Reid is also the Chair of the Palliative Care Research Network at the All-Ireland Institute of Hospice and Palliative Care. She has led local, national and international research projects in cachexia and has received several awards for her work – most recently, this year she was named as a pioneering palliative care nurse by St. Christopher’s Hospice, London.

Maria Rohm
Helmholtz Zentrum München, Germany

Maria Rohm, PhD, is currently Head of the Young Investigator Group at the Helmholtz Zentrum München in Neuherberg, Germany, which aims to understand the molecular basis of metabolic dysfunction in cancer and metabolic diseases. After studying biology at Heidelberg University and the University of Manchester, UK, she obtained her PhD in Biology from the University of Heidelberg in 2012. She was a postdoctoral research fellow at the German Cancer Research Center, Heidelberg, and then at the University of Oxford, UK.

Giuseppe M. C. Rosano
St. George’s University Hospitals NHS Foundation Trust, United Kingdom

Giuseppe M.C. Rosano, MD, PhD, is Professor of Cardiology and Consultant Cardiologist at St. George’s Hospital NHS Trust University of London, United Kingdom where he is also the Director of the MSc in Heart Failure. He received his medical degree and his specialisation in cardiovascular medicine from “La Sapienza” University of Rome in Rome, Italy, and his PhD in Medical Sciences from the Imperial College of Science and Technology in London, United Kingdom. Giuseppe Rosano has authored or co-authored more than 500 peer-reviewed articles. He is the president-elect of the Heart Failure Association of the ESC.

Filippo Rossi Fanelli
Sapienza University of Rome, Italy

Prof. Filippo Rossi-Fanelli received his M.D. Magna Cum Laude from the Sapienza University of Rome, Italy, in 1971, where he also performed his residency in the Department of Internal Medicine, becoming Assistant Professor of Medicine from 1974 to 1982. He was a research fellow, at Harvard Medical School and Massachusetts General Hospital from June 1976 to May 1977. From 1982 to 1988, he was Associate Professor of Medicine and Chief of the Laboratory of Clinical Nutrition, in the Department of Internal Medicine, Sapienza University of Rome, becoming Professor of Medicine from 1988 to 2016 when retired. Since then, he has been Professor Emeritus of Internal Medicine.

Dmitry Rozenberg
University of Toronto, Canada

Dmitry Rozenberg MD, PhD, FRCPC, is a Pulmonologist at the University Health Network and affiliated with the Ajmera Multi-Organ Transplant Program in Toronto, Canada. He is an Assistant Professor in the Department of Medicine, University of Toronto and has been awarded the Sandra Faire and Ivan Fecan Professorship in Rehabilitation Medicine. Dr. Rozenberg’s research aims to understand the impact of physical fitness and skeletal muscle dysfunction on daily physical function, quality of life, frailty, health care use, and survival before and after lung transplantation.

Maurilio Sampaolesi
University of Pavia, Italy

Sampaolesi group has extensive experience in the field of stem cells for disease modeling and their use for the treatment of muscle degeneration. Basic studies related to the roles of epigenetics (methylation and histone code) and miRNAs in myogenic commitments during aging are also main research tasks. Recently, they demonstrated that despite reprogramming of somatic cells to a pluripotent state, the myogenic potential is retained due to a durable epigenetic memory. Combining RNA- and miRNA-sequencing studies and more recently using single cell RNAseq technology, they defined miRNA cocktails that promote the myogenic potential of human mesodermal progenitors. Those approaches are also applied to muscle degeneration, including cachexia and sarcopenia.

Marco Sandri
University of Padova, Italy

Marco Sandri is Full Professor of Pathology at Department of Biomedical Science, University of Padova. In 2005 he was awarded by the prestigious Dulbecco Telethon prize and established his lab at Venetian Institute of Molecular Medicine in Padova. Marco Sandri has also an honorary position as Adjunct Professor at McGill University, Montreal, Canada from 2011. He got the prestigious ERC consolidator grant and is now a reviewer for the European Commission (ERC) and panel member of ERC consolidator program. He is particularly interested in understanding the signaling pathways that control muscle mass with a focus on the role of the ubiquitin-proteasome and autophagy-lysosome systems. He was the first to show a transcriptional-dependent regulation of autophagy and protein breakdown.

Roberta Sartori
University of Padova, Italy

Roberta Sartori gained her PhD in Biosciences – Cellular Biology program – at the Department of Biomedical Sciences at University of Padua. Her postdoctoral training was in the laboratory of Prof. Marco Sandri at the Venetian Institute of Molecular Medicine (VIMM), Padua, Italy and in the laboratory of Prof. Paul Gregorevic at the Baker Heart and Diabetes Institute, Melbourne, Australia. Her research interests focus on regulation of skeletal muscle homeostasis by factors of the TGF-b superfamily. Her publications include: “Smad2 and 3 transcription factors control muscle mass in adulthood” Am J Physiol Cell Physiol. 2009 Jun;296(6):C1248-57 and “BMP signaling controls muscle mass” Nat Genet. 2013 Nov;45(11):1309-18

Jens Schmidt
University Medical Center Goettingen, Germany

Jens Schmidt, MD, Fellow of the American Academy for Neurology (FAAN) and Fellow of the European Academy for Neurology (FEAN), is a consultant and professor of Neurology at the Department of Neurology in Goettingen, Germany. He is head of the Muscle Immunobiology Group and Speaker of the Neuromuscular Center at the University Medical Center Goettingen. The center is member of the European Reference Networks for Neuromuscular Disorders (ERN EURO-NMD) and Dr. Schmidt is the national spokesperson for all German centers and the European spokesperson for the field of myositis within this network. His research interest encompasses a wide range of experimental Muscle Immunobiology as well as clinical and translational Neurology and Myology.

Marilia Seelaender
University of São Paulo, Brazil

Marilia Seelaender, PhD, is currently Head of the Cancer Metabolism Research Group, and Associate Professor in the Department of Surgery, at the Faculty of Medicine, University of São Paulo, Brazil, and also serves as Director, of the Cancer Cachexia Society. She graduated in molecular biologist from the University of Sao Paulo, and obtained her PhD in human physiology there also. She was a research associate in metabolic research at the Radcliffe Infirmary, University of Oxford, UK, in the biochemistry of nutrition, at the University of Potsdam, Germany, and in cancer biochemistry at the University of Barcelona, Spain. Her main field of research is in tissue metabolic and inflammatory crosstalk in cancer cachexia, as well as human cancer cachexia.

Richard Skipworth
University of Edinburgh, United Kingdom

Richard Skipworth is a Consultant General and Upper GastrointestinaI Surgeon at the Royal Infirmary of Edinburgh, and Honorary Reader in Surgery at the University of Edinburgh. He holds the post of NHS Research Scotland Clinician for which he leads a research group that is interested in cachexia, nutritional status, and body composition in cancer patients. Much of his research involves translational and clinical studies in patients with upper GI cancer, with emphases on tissue collection and patient phenotyping. He was awarded the Syme Medal from Royal College of Surgeons of Edinburgh 2012, and the Cuthbertson Award from The Nutrition Society 2020.

Adrian Slee
University College London (UCL), United Kingdom

Dr Adrian Slee is a Lecturer in Nutrition at University College London, UK. He has a BSc degree in Physiology and Biochemistry with Nutrition and PhD in Nutritional Sciences. He has worked at several academic institutions previously as a Lecturer and Course Leader for different Nutrition and Exercise Science related degree courses. His research areas of interest are aligned with a broad range of topics on malnutrition, cachexia, sarcopenia and frailty. Dr Adrian Slee has published in areas such as malnutrition and sarcopenia in frail older people, cachexia and sarcopenia in chronic kidney disease, and malnutrition in heart failure. He is also a Registered Nutritionist with the Association for Nutrition, UK and has several professional exercise practitioner qualifications.

Ashley Smuder
University of Florida, USA

Ashley Smuder, PhD is an Assistant Professor in the Department of Applied Physiology and Kinesiology at the University of Florida. Dr. Smuder received her PhD in Exercise Physiology from the University of Florida where she also completed her post-doctoral training studying skeletal muscle physiology. Work in her laboratory is focused on understanding the molecular signaling pathways that promote cardiac and skeletal muscle dysfunction following disease or periods of prolonged inactivity. Her current research is focused on determining the mechanisms by which physical activity can preserve cardiorespiratory muscle function following exposure to chemotherapy.

Wei Roc Song
Wuhan University School of Medicine, China

Dr. Wei Roc Song, PhD, is currently a Professor in Medical Research Institute at Wuhan University, China. He obtained his PhD in the Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and later worked as a postdoctoral researcher in the Department of Genetics at Harvard Medical School & Howard Hughes Medical Institute in Boston, US As a biological researcher with over 10 years of extensive experience in molecular biology and genetics, he is focusing on molecular elucidation of human metabolic diseases, including diabetes, aging, and tumor-induced wasting.

Pietro Spitali
Leiden University Medical Center, The Netherlands

Pietro Spitali is currently an assistant professor at the Human Genetics Department of the Leiden University Medical Center. He has worked in the field of muscular dystrophies and especially Duchenne muscular dystrophy (DMD) since 2003. His graduate work focused on the pre-clinical development of antisense oligonucleotides mediated exon skipping in DMD. His work focuses on the identification of –omic biomarkers in patients affected by muscular dystrophies and especially Duchenne. Pietro has authored >40 publications in leading journals. His work has been funded by patients charities such as the Prinses Beatrix Spierfonds, the Association française contre les myopathies (AFM), Dutch Duchenne Parent Project and PPMD as well by EU projects.

Florian Strasser
Klinik Gais AG, Switzerland

Dr. Florian Strasser is a specialist in internal medicine, medical oncology and specialist palliative care and as well holds a certification in delegated psychotherapy. He promoted integration of oncology and palliative care, led the European Society of Medical Oncology (ESMO) working group of designated centres for four years, emphasizing double boarded specialist palliative care and medical oncology. A key interest lies in cancer cachexia and both cancer disease and cancer treatment related fatigue syndrome, supportive care issues and survivorship care. Since autumn 2018, he is leading the new integrated cancer rehabilitation clinic in Eastern Switzerland, for all patients with indications for cancer rehabilitation in the full trajectory of curative and non-curative oncology

Erin E. Talbert
University of Iowa, USA

Erin Talbert is an Assistant Professor in the Department of Health and Human Physiology and the Holden Comprehensive Cancer Center at the University of Iowa, USA. Her laboratory is interested in mechanisms driving skeletal muscle wasting in cancer patients and ways in which these losses can be prevented, with a particular interest in how pancreatic cancer causes muscle loss due to the high incidence and severity of wasting in these patients.

Francesco Saverio Tedesco
University College London (UCL), United Kingdom

Dr Tedesco is a clinician-scientist with expertise in neuromuscular diseases and muscle regeneration. He graduated in Medicine and Surgery with honours at the Sapienza University of Rome (Italy). He obtained his PhD investigating novel gene and cell therapies for muscular dystrophy at the San Raffaele Scientific Institute of Milan (Italy). He established his research group at UCL in 2014 and in 2015 he received the Young Investigator Award by the European Society of Gene and Cell Therapy. He was then awarded an NIHR Academic Clinical Fellowship, followed by a Clinical Lectureship and a prestigious €1.5 million European Research Council (ERC) Starting Grant. In 2020 he received the RCPCH Simon Newell Investigator of the Year award, a 6-year attachment at the Francis Crick Institute and was promoted Professor at UCL.

Stephan von Haehling
University of Göttingen Medical Centre, Germany

Stephan von Haehling, MD, PhD, DIC, FESC is a consultant cardiologist and Associate Professor of Medicine at the Department of Cardiology and Pneumology at the University Medical Center Göttingen, Germany. He obtained his MD at the Institute of Immunology at Charité Medical School, Berlin, Germany. His PhD was awarded by Imperial College, London, UK after he completed studies into inflammatory mechanisms of heart failure at the National Heart and Lung Institute in London. Dr. von Haehling has authored more than 250 original research papers, review articles, and editorials. His research interests include the pathophysiology of heart failure, muscle wasting, sarcopenia, biomarkers, cardio-oncology, and novel treatments.

Hidetaka Wakabayashi
Tokyo Women’s Medical University Hospital, Japan

Professor Wakabayashi studied medicine at the Yokohama City University School of Medicine obtaining his MD in 1995, and obtained his PhD in 2016 from the Jikei University Graduate School of Medicine, in Japan. After obtaining his MD, he continued to work in Yokohama in rehabilitation medicine and was recently appointed Professor in the Department of Rehabilitation Medicine in the Tokyo Women’s Medical University Hospital.He is a board member of the Society on Sarcopenia, Cachexia and Wasting Disorders, Associate Editor of the Journal of Cachexia, Sarcopenia and Muscle, and chairperson and editorial board member of the Japanese Association of Rehabilitation Nutrition.

Xiaonan Wang
Emory University, USA

Dr. Xiaonan Wang gained his MD in 1982 from Peking Union Medical College, Beijing, China. She finished her post-doc training in 1991 in the University of Colorado HSC, Denver, CO and in 1997 in Emory University, Atlanta, GA, USA. Currently, Dr. Wang is an Associate Professor of Renal Division, Department of medicine. She has published 78 papers in peer review journal. Since 1997, Dr. Wang has focused on investigation of the molecular/cellular mechanisms that lead to protein malnutrition in diabetes, chronic kidney disease and aging in order to develop therapeutic strategies for treatment.
Dr. Wang uses transgenic mice, virus (adenovirus, adeno-associated virus (AAV) and lentivirus) and exosome mediated gene transfer and cell culture systems to test her hypotheses.

David L. Waning
Penn State College of Medicine, USA

Dr. Waning received his Ph.D. in Biochemistry and Molecular Biology at Northwestern University in Evanston, IL and did his post-doctoral work at the Indiana University School of Medicine in Indianapolis, IN. Currently his research is focused on improving musculoskeletal health in models of cancer and chemotherapy, osteoporosis and aging. The lab uses a wide array of in vivo and biochemical approaches to study skeletal muscle function and bone-muscle crosstalk.

Jochen Weishaupt
Medical Faculty Mannheim, Heidelberg University, Germany

Jochen Weishaupt studied at the Heidelberg Medical School from 1992-1998, earning his MD (summa cum laude) investigating glutamate receptor neurobiology in the laboratories of Peter H. Seeburg (ZMBH) and Bert Sakmann. Jochen Weishaupt joined the laboratory of Mathias Baehr in Tübingen, and graduated from Tübingen Medical School in 1999. He spent part of his practical year in the Massachusetts General Hospital, Harvard Medical School, and the Beth Israel Medical Centre, Albert Einstein College, New York, USA. He specialized in neurology in 2007 and was an attending neurologist at the University of Göttingen until 2011. Between 2012 and July 2020, he was Endowed W3 Professor in Neurodegeneration at the Ulm University. He is currently Head of the Section for Neurodegeneration in the Neurology Department at the Medical Faculty Mannheim, Heidelberg University, Germany.

Joachim Wiskemann
University Heidelberg, Germany

Joachim Wiskemann holds a PhD and is habilitated in sports and exercise science with an additional academic education in sports psychology. He is employed at the National Center for Tumor Diseases / University Heidelberg and Adjunct Assistant Professor of Public Health Science at Penn State University. As head of the working group “Exercise Oncology ” (Division of Medical Oncology, National Center for Tumor Diseases (NCT) and Heidelberg University Hospital) and principal/co-investigator of several exercise intervention trials in cancer patients he has substantial experience in planning and tailoring exercise programs to cancer patients´ needs and capabilities and conducted exercise studies in cancer patients for more than ten years.

Zhidan Wu
Pfizer, USA

Dr. Zhidan Wu received her Ph.D. in Chemistry from Boston University. She did her post-doctoral work at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Wu is a Senior Scientific Director in the Internal Medicine Research Unit at Pfizer. Prior to joining Pfizer in 2016, she was a senior research investigator at Novartis.

Bei B. Zhang
Pfizer Worldwide Research, Development & Medical in Cambridge, USA

Dr. Bei B. Zhang is a seasoned pharmaceutical executive and a proven leader. She is currently Vice President at Pfizer Worldwide Research, Development & Medical in Cambridge, MA, USA. She is leading research from setting strategy to advancing projects in the pipeline in multiple disease areas including cancer cachexia and cachexia associated with chronic diseases, heart failure, PAH, and metabolic disorders, as well as the state-of-the-art technology and omics platforms to enable innovation and discovery. Dr. Zhang has an excellent track record of scientific accomplishment illustrated by lectures at numerous scientific conferences and over 145 original articles in peer-reviewed scientific journals.

Teresa Zimmers
Roudebush Veterans Administration Medical Center, USA

Teresa Zimmers, PhD, received her BS in Biology from the Massachusetts Institute of Technology. She earned her PhD in Molecular Biology and Genetics from the Johns Hopkins University School of Medicine and spent her postdoctoral years at the University of Rochester School of Medicine. She obtained her first faculty job at the University of Miami Miller School of Medicine then moved briefly to the Thomas Jefferson University School of Medicine’s Kimmel Cancer Center, before taking a position at the Indiana University School of Medicine in Indianapolis in 2013. She is currently the HH Gregg Professor of Cancer Research and Professor of Surgery and Research Health Scientist at the Roudebush Veterans Administration Medical Center in Indianapolis.

Antonio Zorzano
University of Barcelona, Spain

Antonio Zorzano is Full Professor of Biochemistry and Molecular Biology at the University of Barcelona, Director of Complex metabolic diseases and mitochondria laboratory at the IRB Barcelona, and Programme Head at CIBERDEM. Professor Zorzano received his PhD in Biology at the University of Barcelona, and did postdoctoral studies with Emilio Herrera (Hospital Ramon y Cajal, Madrid), Neil Ruderman (Boston University Medical Center), and Paul Pilch (Boston University Medical School). He is co-inventor of 21 patents, and has published over 330 scientific articles (more than 34,000 citations), with key discoveries published in leading journals, and an h-index of 85 (Google Scholar). He has been founder of biotechnological companies in Spain and in UK.